Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106


A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC).

Hwang JW, Loisel-Duwattez J, Desterke C, Latsis T, Pagliaro S, Griscelli F, Bennaceur-Griscelli A, Turhan AG.

Biochim Biophys Acta Gen Subj. 2020 Apr;1864(4):129540. doi: 10.1016/j.bbagen.2020.129540. Epub 2020 Jan 21.


iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma.

Hwang JW, Desterke C, Féraud O, Richard S, Ferlicot S, Verkarre V, Patard JJ, Loisel-Duwattez J, Foudi A, Griscelli F, Bennaceur-Griscelli A, Turhan AG.

Int J Mol Sci. 2019 Sep 30;20(19). pii: E4867. doi: 10.3390/ijms20194867.


Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.

Balducci E, Sanekli S, Hugues P, Soubeyrand M, Borie C, Fund X, Desterke C, Aumont C, Faivre J, Bennaceur-Griscelli A, Turhan AG.

Leuk Lymphoma. 2020 Jan;61(1):209-212. doi: 10.1080/10428194.2019.1658101. Epub 2019 Aug 29. No abstract available.


Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations.

Griscelli F, Desterke C, Feraud O, Divers D, Oudrhiri N, Tosca L, Turhan AG, Bennaceur-Griscelli A.

Oncotarget. 2019 Apr 12;10(28):2693-2708. doi: 10.18632/oncotarget.26857. eCollection 2019 Apr 12.


Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells.

Flamant S, Chomel JC, Desterke C, Féraud O, Gobbo E, Mitjavila-Garcia MT, Foudi A, Griscelli F, Turhan AG, Bennaceur-Griscelli A.

Int J Mol Sci. 2019 Apr 8;20(7). pii: E1737. doi: 10.3390/ijms20071737.


Clinically silent indolent T-cell leukemia.

Janot C, Feriel J, Borie C, Lefevre E, Bennaceur-Griscelli A, Turhan AG, Aumont C.

Clin Case Rep. 2018 Nov 10;7(1):24-26. doi: 10.1002/ccr3.1528. eCollection 2019 Jan.


Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).

Gentil M, Hugues P, Desterke C, Telliam G, Sloma I, Souza LEB, Baykal S, Artus J, Griscelli F, Guerci A, Johnson-Ansah H, Foudi A, Bennaceur-Griscelli A, Turhan AG.

PLoS One. 2018 Aug 9;13(8):e0200923. doi: 10.1371/journal.pone.0200923. eCollection 2018.


Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy.

Sandt C, Feraud O, Bonnet ML, Desterke C, Khedhir R, Flamant S, Bailey CG, Rasko JEJ, Dumas P, Bennaceur-Griscelli A, Turhan AG.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1861-1867. doi: 10.1016/j.bbrc.2018.07.127. Epub 2018 Jul 26.


Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).

Desterke C, Voldoire M, Bonnet ML, Sorel N, Pagliaro S, Rahban H, Bennaceur-Griscelli A, Cayssials E, Chomel JC, Turhan AG.

Exp Hematol. 2018 Aug;64:71-83.e8. doi: 10.1016/j.exphem.2018.04.007. Epub 2018 May 5.


Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 3 (MODY3) carrying a hepatocyte nuclear factor 1-alpha (HNF1A) mutation.

Griscelli F, Ezanno H, Soubeyrand M, Feraud O, Oudrhiri N, Bonnefond A, Turhan AG, Froguel P, Bennaceur-Griscelli A.

Stem Cell Res. 2018 May;29:56-59. doi: 10.1016/j.scr.2018.02.017. Epub 2018 Mar 7.


Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.

Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG.

Biochem Biophys Res Commun. 2018 Apr 15;498(4):715-722. doi: 10.1016/j.bbrc.2018.03.023. Epub 2018 Mar 17.


Transcriptional landscape of a RETC634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers.

Hadoux J, Desterke C, Féraud O, Guibert M, De Rose RF, Opolon P, Divers D, Gobbo E, Griscelli F, Schlumberger M, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2018 Jan;26:8-16. doi: 10.1016/j.scr.2017.11.015. Epub 2017 Nov 23.


Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.

Griscelli F, Oudrhiri N, Feraud O, Divers D, Portier L, Turhan AG, Bennaceur Griscelli A.

Stem Cell Res. 2017 Oct;24:135-138. doi: 10.1016/j.scr.2017.09.003. Epub 2017 Sep 14.


Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 13 (MODY13) with a the potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) mutation.

Griscelli F, Feraud O, Ernault T, Oudrihri N, Turhan AG, Bonnefond A, Froguel P, Bennaceur-Griscelli A.

Stem Cell Res. 2017 Aug;23:178-181. doi: 10.1016/j.scr.2017.07.023. Epub 2017 Jul 25.


Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation.

Bennaceur-Griscelli A, Hadoux J, Féraud O, Opolon P, Divers D, Gobbo E, Schlumberger M, Griscelli F, Turhan AG.

Stem Cell Res. 2017 Aug;23:154-157. doi: 10.1016/j.scr.2017.07.022. Epub 2017 Jul 22.


Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.


Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.

Sloma I, Mitjavila-Garcia MT, Feraud O, Griscelli F, Oudrhiri N, El Marsafy S, Gobbo E, Divers D, Proust A, Smadja DM, Desterke C, Carles A, Ma Y, Hirst M, Marra MA, Eaves CJ, Bennaceur-Griscelli A, Turhan AG.

Exp Hematol. 2017 Sep;53:48-58. doi: 10.1016/j.exphem.2017.05.007. Epub 2017 Jun 8.


Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.

Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X.

Oncotarget. 2017 Jul 4;8(27):43662-43677. doi: 10.18632/oncotarget.18216.


Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.

Telliam G, Féraud O, Griscelli F, Opolon P, Divers D, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2016 Sep;17(2):235-237. doi: 10.1016/j.scr.2016.08.001. Epub 2016 Aug 4.


In vitro culture and phenotypic and molecular characterization of gastric stem cells from human stomach.

Garcia M, Chomel JC, Mustapha P, Tran CT, Garnier M, Paris I, Quellard N, Godet J, Cremniter J, Bennaceur-Griscelli A, Lecron JC, Turhan AG, Burucoa C, Bodet C.

Helicobacter. 2017 Apr;22(2). doi: 10.1111/hel.12351. Epub 2016 Sep 4.


Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation.

Hadoux J, Féraud O, Griscelli F, Opolon P, Divers D, Gobbo E, Schlumberger M, Bennaceur-Griscelli A, Turhan AG.

Stem Cell Res. 2016 Jul;17(1):154-157. doi: 10.1016/j.scr.2016.06.008. Epub 2016 Jun 27.


Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.

Vatel O, Aumont C, Mathy V, Petit M, Feriel J, Sloma I, Bennaceur-Griscelli A, Turhan AG.

Leuk Lymphoma. 2017 Feb;58(2):473-474. Epub 2016 Jul 7. No abstract available.


Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.

Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG.

Oncotarget. 2016 Jun 7;7(23):35293-301. doi: 10.18632/oncotarget.9182.


Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia.

Turhan AG.

Leuk Lymphoma. 2016 Nov;57(11):2731-2. doi: 10.3109/10428194.2016.1163346. Epub 2016 Apr 14. No abstract available.


The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.

Dkhissi F, Aggoune D, Pontis J, Sorel N, Piccirilli N, LeCorf A, Guilhot F, Chomel JC, Ait-Si-Ali S, Turhan AG.

Exp Hematol. 2015 Sep;43(9):775-80. doi: 10.1016/j.exphem.2015.04.013. Epub 2015 Jun 26.


Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.

Aggoune D, Tosca L, Sorel N, Bonnet ML, Dkhissi F, Tachdjian G, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Oncoscience. 2014 Jan 30;1(1):57-68. eCollection 2014.


Morphological analysis of human induced pluripotent stem cells during induced differentiation and reverse programming.

Courtot AM, Magniez A, Oudrhiri N, Féraud O, Bacci J, Gobbo E, Proust S, Turhan AG, Bennaceur-Griscelli A.

Biores Open Access. 2014 Oct 1;3(5):206-16. doi: 10.1089/biores.2014.0028.


Generation of multipotent early lymphoid progenitors from human embryonic stem cells.

Larbi A, Mitjavila-Garcia MT, Flamant S, Valogne Y, Clay D, Usunier B, l'Homme B, Féraud O, Casal I, Gobbo E, Divers D, Chapel A, Turhan AG, Bennaceur-Griscelli A, Haddad R.

Stem Cells Dev. 2014 Dec 15;23(24):2983-95. doi: 10.1089/scd.2014.0171.


[Chronic myeloid leukemia stem cells: cross-talk with the niche].

Chomel JC, Aggoune D, Sorel N, Turhan AG.

Med Sci (Paris). 2014 Apr;30(4):452-61. doi: 10.1051/medsci/20143004022. Epub 2014 May 5. Review. French.


Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation.

Baulier E, Favreau F, Le Corf A, Jayle C, Schneider F, Goujon JM, Feraud O, Bennaceur-Griscelli A, Hauet T, Turhan AG.

Stem Cells Transl Med. 2014 Jul;3(7):809-20. doi: 10.5966/sctm.2013-0186. Epub 2014 May 5.


Haemophagocytic histiocyte in a peripheral blood film.

Sloma I, Vincent H, Addebbous A, Rivoisy C, Turhan AG, Michot JM.

Br J Haematol. 2014 Apr;165(2):163. doi: 10.1111/bjh.12697. Epub 2013 Dec 28. No abstract available.


Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I.

Cancer Res. 2013 Apr 1;73(7):2052-8. doi: 10.1158/0008-5472.CAN-12-3955. Epub 2013 Feb 11.


Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.

Melkus M, Bennaceur-Griscelli A, Valogne Y, Flamant S, Chomel JC, Sorel N, Bonnet ML, Deininger MW, Mitjavila-Garcia MT, Turhan AG.

Exp Hematol. 2013 Apr;41(4):335-45.e3. doi: 10.1016/j.exphem.2012.12.004. Epub 2012 Dec 31.


O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.

Int J Mol Sci. 2012;13(6):6983-94. doi: 10.3390/ijms13066983. Epub 2012 Jun 7.


The HOXB4 homeoprotein promotes the ex vivo enrichment of functional human embryonic stem cell-derived NK cells.

Larbi A, Gombert JM, Auvray C, l'Homme B, Magniez A, Féraud O, Coulombel L, Chapel A, Mitjavila-Garcia MT, Turhan AG, Haddad R, Bennaceur-Griscelli A.

PLoS One. 2012;7(6):e39514. doi: 10.1371/journal.pone.0039514. Epub 2012 Jun 27.


Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.

Rossignol A, Levescot A, Jacomet F, Robin A, Basbous S, Giraud C, Roy L, Guilhot F, Turhan AG, Barra A, Herbelin A, Gombert JM.

Eur J Immunol. 2012 Jul;42(7):1870-5. doi: 10.1002/eji.201142043.


Identification of spectral modifications occurring during reprogramming of somatic cells.

Sandt C, Féraud O, Oudrhiri N, Bonnet ML, Meunier MC, Valogne Y, Bertrand A, Raphaël M, Griscelli F, Turhan AG, Dumas P, Bennaceur-Griscelli A.

PLoS One. 2012;7(4):e30743. doi: 10.1371/journal.pone.0030743. Epub 2012 Apr 13.


BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia.

Chomel JC, Sorel N, Guilhot J, Guilhot F, Turhan AG.

Blood. 2012 Mar 22;119(12):2964-5; author reply 2965-6. doi: 10.1182/blood-2011-12-396226. No abstract available.


Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.

Griscelli F, Féraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC, Biéche I, Duvillard P, Opolon P, Turhan AG, Bennaceur-Griscelli A.

Am J Pathol. 2012 May;180(5):2084-96. doi: 10.1016/j.ajpath.2012.01.011. Epub 2012 Mar 13.


Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.

Mayeur-Rousse C, Sorel N, Voldoire M, Canioni D, Brizard F, Randriamalala E, Turhan AG, Chomel JC.

Leuk Res. 2012 Mar;36(3):377-81. doi: 10.1016/j.leukres.2011.10.009. Epub 2011 Oct 24. No abstract available.


Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F, Turhan AG.

Blood. 2011 Sep 29;118(13):3657-60. doi: 10.1182/blood-2011-02-335497. Epub 2011 Jul 25.


STAT5 as a CML target: STATinib therapies?

Turhan AG.

Blood. 2011 Mar 24;117(12):3252-3. doi: 10.1182/blood-2011-01-332569. No abstract available.


Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan AG.

Leuk Lymphoma. 2010 Nov;51(11):2103-11. doi: 10.3109/10428194.2010.520774. Epub 2010 Oct 7.


Partial reversal of the methylation pattern of the X-linked gene HUMARA during hematopoietic differentiation of human embryonic stem cells.

Mitjavila-Garcia MT, Bonnet ML, Yates F, Haddad R, Oudrhiri N, Féraud O, Magniez A, Makhlouf M, Vallot C, Rougeulle C, Bennaceur-Griscelli A, Turhan AG.

J Mol Cell Biol. 2010 Oct;2(5):291-8. doi: 10.1093/jmcb/mjq026. Epub 2010 Sep 7.


Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.

Sorel N, Mayeur-Rousse C, Deverrière S, Roy L, Brottier-Mancini E, Guilhot F, Turhan AG, Chomel JC.

J Mol Diagn. 2010 Jul;12(4):520-4. doi: 10.2353/jmoldx.2010.090218. Epub 2010 May 27.


STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?

Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, Tourani JM, Dusanter-Fourt I, Turhan AG, Karayan-Tapon L.

Int J Cancer. 2011 Feb 15;128(4):826-38. doi: 10.1002/ijc.25416.


Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.

Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE.

Haematologica. 2010 Aug;95(8):1325-33. doi: 10.3324/haematol.2009.020636. Epub 2010 May 11.


Toxicity and phototoxicity of Hypocrellin A on malignant human cell lines, evidence of a synergistic action of photodynamic therapy with Imatinib mesylate.

Chio-Srichan S, Oudrhiri N, Bennaceur-Griscelli A, Turhan AG, Dumas P, Refregiers M.

J Photochem Photobiol B. 2010 May 3;99(2):100-4. doi: 10.1016/j.jphotobiol.2010.03.001. Epub 2010 Mar 6.


Tyrosine phosphorylation of SHIP promotes its proteasomal degradation.

Ruschmann J, Ho V, Antignano F, Kuroda E, Lam V, Ibaraki M, Snyder K, Kim C, Flavell RA, Kawakami T, Sly L, Turhan AG, Krystal G.

Exp Hematol. 2010 May;38(5):392-402, 402.e1. doi: 10.1016/j.exphem.2010.03.010. Epub 2010 Mar 18.


Supplemental Content

Loading ...
Support Center